Current Report Filing (8-k)
November 10 2022 - 08:11AM
Edgar (US Regulatory)
0001813814false00018138142022-11-102022-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
November 10, 2022
MIND MEDICINE (MINDMED) INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
British Columbia,
Canada
|
001-40360
|
98-1582438
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
One World Trade Center,
Suite 8500
New York,
New York
|
|
10007
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code:
(650)
208-2454
Not Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Shares
|
MNMD
|
The Nasdaq Stock Market LLC
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
|
|
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 10, 2022, Mind Medicine (MindMed) Inc. (the “Company”)
issued a press release announcing its financial results for its
fiscal quarter ended September 30, 2022
as well as information regarding a conference call to discuss these
financial results and the Company’s recent corporate
highlights.
A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information contained in this Item 2.02 of this Current Report
(including Exhibit 99.1) is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that Section, nor shall it be deemed incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly
authorized.
|
|
|
|
|
|
|
MIND MEDICINE (MINDMED) INC.
|
|
|
|
|
|
|
Date: November 10, 2022
|
|
By:
|
/s/ Robert Barrow
|
|
|
|
Name:
|
Robert Barrow
|
|
|
|
Title:
|
Chief Executive Officer
|
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Feb 2023 to Mar 2023
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Mar 2022 to Mar 2023
